Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis

Company Overview

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in South San Francisco, California, focused on the discovery, development and commercialization of novel small-molecule drugs targeting signaling pathways involved in inflammation, oncology and immunology. Since its founding in 1996, Rigel has built a robust discovery platform centered on kinase inhibitors and other enzyme modulators, leveraging proprietary chemistry and target-validation approaches to advance programs from early research through clinical development.

The company’s lead marketed product is fostamatinib (Tavalisse), an oral spleen tyrosine kinase (SYK) inhibitor approved for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Tavalisse has also been studied in additional immuno-inflammatory conditions. Beyond its marketed therapy, Rigel maintains a diversified pipeline that includes selective inhibitors of kinases such as RIPK1 and IRAK4, as well as novel small molecules aimed at oncology targets. Several of these programs are advancing through Phase 1 and Phase 2 clinical trials, either internally or in collaboration with partners.

Rigel’s research and development efforts extend across North America and collaborate with global biopharmaceutical companies. The company has forged strategic partnerships and licensing agreements to optimize late-stage development and commercialization, notably expanding its geographic reach in Europe and Asia. Rigel’s scientific teams operate from cutting-edge laboratory facilities in California, enabling rapid translation of laboratory findings into clinical candidates.

Leadership at Rigel is led by President and Chief Executive Officer Pablo Ledesma, Ph.D., who has guided the company through key regulatory milestones and commercial launches. Supported by a seasoned management team with deep expertise in drug discovery, clinical development and commercial strategy, Rigel remains committed to advancing its portfolio of targeted therapies to address unmet medical needs in immune-related disorders and oncology.

Key Stats

• Today's Range: $18.63 to $19.49
• 50-Day Range: $18.26 to $21.85
• 52-Week Range: $8.61 to $29.82
• Volume: 212,770 shs
• Average Volume: 210,713 shs
• Market Capitalization: $337.39 million
• P/E Ratio: 9.12
• Dividend Yield: N/A
• Price Target: $36.40
• Consensus Rating: Hold

Rigel Pharmaceuticals Stock Analysis - MarketRank™

Rigel Pharmaceuticals scored higher than 60% of companies evaluated by MarketBeat, and ranked 425th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Rigel Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Rigel Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 377.27%

Earnings Growth

Earnings for Rigel Pharmaceuticals are expected to grow by 377.27% in the coming year, from $0.22 to $1.05 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rigel Pharmaceuticals is 9.12, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.90.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rigel Pharmaceuticals is 9.12, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.96.

Price to Book Value per Share Ratio

Rigel Pharmaceuticals has a P/B Ratio of 99.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.49% of the float of Rigel Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Rigel Pharmaceuticals has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Rigel Pharmaceuticals has recently increased by 3.33%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rigel Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Rigel Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.49% of the float of Rigel Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Rigel Pharmaceuticals has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Rigel Pharmaceuticals has recently increased by 3.33%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 1.17

News Sentiment

Rigel Pharmaceuticals has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Rigel Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for RIGL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Rigel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rigel Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.48% of the stock of Rigel Pharmaceuticals is held by insiders.

Percentage Held by Institutions

66.23% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RIGL Stock Analysis - Frequently Asked Questions

How have RIGL shares performed this year?

Rigel Pharmaceuticals' stock was trading at $16.82 at the start of the year. Since then, RIGL shares have increased by 12.2% and is now trading at $18.88.

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced its earnings results on Tuesday, May, 6th. The biotechnology company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.49. The biotechnology company earned $53.33 million during the quarter, compared to analysts' expectations of $43.87 million. Rigel Pharmaceuticals had a negative trailing twelve-month return on equity of 655.26% and a net margin of 18.31%.
Read the conference call transcript.

When did Rigel Pharmaceuticals' stock split?

Shares of Rigel Pharmaceuticals reverse split on the morning of Thursday, June 27th 2024.The 1-10 reverse split was announced on Thursday, June 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Rigel Pharmaceuticals' major shareholders?

Top institutional investors of Rigel Pharmaceuticals include Assenagon Asset Management S.A. (1.34%). Insiders that own company stock include Raul R Rodriguez, Dean L Schorno and David A Santos.
View institutional ownership trends.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rigel Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Energy Transfer (ET), SPDR S&P 500 ETF Trust (SPY) and CRISPR Therapeutics (CRSP).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RIGL
• CIK: 1034842
• Web: www.rigel.com
• Phone: (650) 624-1100
• Fax: 650-624-1101
• Employees: 160
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Rigel Pharmaceuticals: $36.40
• High Price Target: $57.00
• Low Price Target: $23.00
• Potential Upside/Downside: +92.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.07
• Trailing P/E Ratio: 9.12
• Forward P/E Ratio: 85.82
• P/E Growth: N/A
• Net Income: $17.49 million
• Net Margins: 18.31%
• Pretax Margin: 18.77%
• Return on Equity: -655.26%
• Return on Assets: 24.47%

Debt

• Debt-to-Equity Ratio: 2.42
• Current Ratio: 2.20
• Quick Ratio: 2.13

Sales & Book Value

• Annual Sales: $179.28 million
• Price / Sales: 1.88
• Cash Flow: $1.07 per share
• Price / Cash Flow: 17.65
• Book Value: $0.19 per share
• Price / Book: 99.37

Miscellaneous

• Outstanding Shares: 17,870,000
• Free Float: 16,178,000
• Market Cap: $337.39 million
• Optionable: Optionable
• Beta: 1.26